Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CervoMed ( (CRVO) ) has shared an update.
CervoMed Inc. announced that its RewinD-LB Phase 2b trial for dementia with Lewy bodies did not meet primary and secondary endpoints, as target drug concentrations were not achieved. Despite the setback, the safety profile of neflamapimod was favorable, and the company plans to analyze the data further before continuing with future trials. The trial was partially funded by a grant from the National Institutes of Health.
For an in-depth examination of CRVO stock, go to TipRanks’ Stock Analysis page.